BPC-157 has a real, unusually stable structure and a genuinely striking animal-trial record — and almost no controlled human data, an FDA compounding ban, and a supply chain that self-injects with no regulatory floor under it. Here's what the evidence actually supports.
Biotech
-
BPC-157 and the Research-Peptide Gray Market -
Collagen Peptides: What the Evidence Actually Says Collagen supplements get digested like any other protein, which should mean they can't reach your skin intact — except a specific dipeptide reliably does. The mechanism is real and measurable. Whether it translates into a benefit worth paying for depends heavily on who funded the trial you're reading.
-
GHRH and GHRP Secretagogues: Asking the Pituitary Instead of Replacing It Sermorelin, ipamorelin, and their relatives don't put growth hormone into your body — they ask your pituitary to make more of its own, through two distinct receptor pathways that leave the body's natural feedback loop intact. That distinction is real, but it doesn't make the anti-aging marketing built on top of it true.
-
Melanotan and the Peptide Underground The same 1980s skin-cancer-prevention research that produced an FDA-approved drug for a rare light-sensitivity disorder also produced melanotan II — a gray-market tanning peptide whose non-selective receptor binding causes the appetite and libido effects users chase and the mole changes, priapism, and cardiac events regulators warn about.
-
Multi-Receptor Peptide Design: One Molecule, Several Targets Tirzepatide hits two receptors and retatrutide hits three, and neither is a gimmick. Here's how agonism, antagonism, and biased signaling actually work at the receptor level, and why combining several of them in one peptide became the dominant strategy in metabolic drug design.
-
Oral Peptide Delivery: Getting a Molecule Past the Gut Alive Peptides are built to be destroyed by digestion, which is exactly what makes swallowing them as a drug so hard. Here's why the gut is a molecular gauntlet, and how SNAC, enteric coatings, robotic capsules, and nanoparticles are each trying to beat it.
-
Retatrutide: The Triple Agonist Pushing Past Tirzepatide Retatrutide's third receptor mechanism has produced the largest weight-loss and liver-fat numbers of any peptide therapeutic tested so far, and an eight-trial Phase 3 program to match. It also has a documented heart-rate signal the earlier drugs in its class don't carry.